Patent Spotlight

Laboratorio de Biología Celular, Centro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro Social, Metepec, Puebla, CP 74360, México

Search for more papers by this author

Martin Perez-Santos

*Author for correspondence:

E-mail Address: martin.perez@correo.buap.mx

https://orcid.org/0000-0001-5074-2000

Dirección de Innovación y Transferencia de Conocimiento, Benemérita Universidad Autónoma de Puebla, Puebla, CP 72570, México

Search for more papers by this author

Published Online:8 Dec 2021https://doi.org/10.4155/ppa-2021-0016

View article

Abstract

Inhibition of the PD-1/PD-L1 pathway is a target for the development of new therapies. US10710986 patent describes a small molecule that targets PDL-1/PD-1 interactions and triggers antitumor activity against colorectal cancer. However, it does not describe biological assays that allow us to suppose that this small molecule may be active in other types of cancer. So far, there are no reports of clinical trials to evaluate the safety, toxicity and efficacy, but it will be of great interest to analyze in the future if this compound surpasses the action of therapy in cancer.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD L1 checkpoint. Immunity 48, 434–452 (2018).
Medline CASGoogle Scholar
2. Monneur A, Goncalves A, Bertucci F. PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer. Bull Cancer 105(3), 263–274 (2018).
MedlineGoogle Scholar
3. Ma L, Lv J, Dong Y et al. PD-L1 expression and its regulation in lung adenocarcinoma with ALK translocation. Interdiscip. Sci. Comput. Life Sci. 11(2), 266–272 (2019).
Medline CASGoogle Scholar
4. He PX, Ma ZL, Han H et al. Expression of programmed death ligand 1 (PD-L1) is associated with metastasis and differentiation in gastric cancer. Life Sci. 242, 117247 (2020).
Medline CASGoogle Scholar
5. Schütz F, Stefanovic S, Mayer L et al. PD-1/PD-L1 pathway in breast cancer. Oncol. Res. Treat. 40(5), 294–297 (2017).
Medline CASGoogle Scholar
6. Payandeh Z, Khalili S, Somi MH et al. PD-1/PD-L1 dependent immune response in colorectal cancer. J. Cell. Physiol. 235(7–8), 5461–5475 (2020).
Medline CASGoogle Scholar
7. Santini FC, Hellmann MD. PD-1/PD-L1 axis in lung cancer. Cancer J. 24(1), 15–19 (2018).
Medline CASGoogle Scholar
8. Markham A. Atezolizumab: first global approval. Drugs 76(12), 1227–1232 (2016).
Medline CASGoogle Scholar
9. Syed YY. Durvalumab: first global approval. Drugs 77(12), 1369–1376 (2017).
Medline CASGoogle Scholar
10. Kim ES. Avelumab: first global approval. Drugs 77(8), 929–937 (2017).
MedlineGoogle Scholar
11. Koppolu V, Vasigala VKR. Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma. J. Cancer Res. Ther. 14(6), 1167–1175 (2018).
Medline CASGoogle Scholar
12. Poole RM. Pembrolizumab: first global approval. Drugs 74(16), 1973–1981 (2014).
Medline CASGoogle Scholar
13. Naidoo J, Page DB, Li BT et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann. Oncol. 26, 2375–2391 (2015).
Medline CASGoogle Scholar
14. Marcucci F, Bellone M, Rumio C et al. Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells. MAbs 5(1), 34–46 (2013).
MedlineGoogle Scholar
15. Yamaguchi S, Morimoto R, Okumura T et al. Late-onset fulminant myocarditis with immune checkpoint inhibitor nivolumab. Can. J. Cardiol. 34(6), 812–e1 (2018).
MedlineGoogle Scholar
16. Zafar Z, Vogle C, Hudali T et al. Nivolumab-associated acute demyelinating encephalitis: a case report and literature review. Clin. Med. Res. 17(1–2), 29–33 (2019).
MedlineGoogle Scholar
17. Martinez-Calle N, Rodriguez-Otero P, Villar S et al. Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity. Haematologica 103(7), e318 (2018).
Medline CASGoogle Scholar
18. Gupta R, Zaid S, Sayed A et al. Atezolizumab induced myocarditis on a background of cardiac amyloidosis. Am. J. Ther. 26(6), e795–e7 (2019).
MedlineGoogle Scholar
19. Arakawa M, Yamazaki M, Toda Y et al. Atezolizumab-induced encephalitis in metastatic lung cancer: a case report and literature review. eNeurologicalSci 14, 49 (2019).
MedlineGoogle Scholar
20. Mahmood SS, Chen CL, Shapnik N et al. Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: a case report. Gynecol. Oncol. Rep. 25, 74–77 (2018).
MedlineGoogle Scholar
21. Carrera W, Baartman BJ, Kosmorsky G. A case report of drug-induced myopathy involving extraocular muscles after combination therapy with tremelimumab and durvalumab for non-small-cell lung cancer. Neuroophthalmology 41(3), 140–143 (2017).
MedlineGoogle Scholar
22. Brie V, Faure M, Garon J et al. Drug-induced interstitial pneumonitis due to avelumab: a case report. Rev. Mal. Respir. 35(9), 978–982 (2018).
Medline CASGoogle Scholar
23. Wu Q, Jiang L, Li SC et al. Small-molecule inhibitors targeting the PD-1/PD-L1 signaling pathway. Acta Pharmacol. Sin. 42(1), 1–9 (2021). • Summarize small-molecule inhibitors of PD-1/PD-L1 based on different therapeutic approaches: blocking direct interaction between PD-1 and PD-L1, inhibiting transcription and translation of PD-L1 and promoting degradation of PD-L1 protein.
Medline CASGoogle Scholar
24. Chen S, Song Z, Zhang A. Small-molecule immuno-oncology therapy: advances challenges and new directions. Curr. Top Med Chem. 19(3), 180–185 (2019).
Medline CASGoogle Scholar
25. Li K, Tian H. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy. J. Drug Targeting 27(3), 244–256 (2019).
Medline CASGoogle Scholar
26. Jiao P, Geng Q, Jin P et al. Small molecules as PD-1/PD-L1 pathway modulators for cancer immunotherapy. Curr. Phar. Des. 24(41), 4911–4920 (2018).
Medline CASGoogle Scholar
27. Chen T, Li Q, Liu Z et al. Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: a new choice for immunotherapy? Eur. J. Med. Chem. 161, 378–398 (2019).
Medline CASGoogle Scholar
28. Wang T, Wu X, Guo C et al. Development of inhibitors of the programmed cell death-1/programmed cell death-ligand 1 signaling pathway. J. Med. Chem. 62(4), 1715–1730 (2018).
MedlineGoogle Scholar
29. Shaabani S, Huizinga HP, Butera R et al. A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015–2018). Expert Opin. Ther. Pat. 28(9), 665–678 (2018). •• Discusses patent applications on small molecules classes and peptides targeting PD1/PD-L1
Medline CASGoogle Scholar
30. Guzik K, Tomala M, Muszak D et al. Development of the inhibitors that target the PD-1/PD-L1 interaction-a brief look at progress on small molecules, peptides and macrocycles. Molecules 24(11), 2071 (2019).
CASGoogle Scholar
31. Magiera-Mularz K, Skalniak L, Zak KM et al. Bioactive macrocyclic inhibitors of the PD-1/PD-L1 immune checkpoint. Angew. Chem. Int. Ed. Engl. 56(44), 13732–13735 (2017).
Medline CASGoogle Scholar
32. Gilead Sciences: US10710986 (2020).
Google Scholar
34. Ahmadzadeh M, Johnson LA, Heemskerk B et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114(8), 1537–1544 (2009).
Medline CASGoogle Scholar
35. Zhang M, Sun H, Zhao S et al. Expression of PD-L1 and prognosis in breast cancer: a meta-analysis. Oncotarget 8(19), 31347 (2017).
MedlineGoogle Scholar
36. Qiu YJ, Zhang MZ. PD-L1 expression is related with prognosis of small cell lung cancer. Zhonghua Zhong Liu Za Zhi. 41(3), 214–217 (2019).
Medline CASGoogle Scholar
37. Zhao B, Zhao H, Zhao J. Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials. Ther. Adv. Med. Oncol. 12, 1–12 (2020).
Google Scholar
38. Ashrafizadeh M, Zarrabi A, Hushmandi K et al. PD-1/PD-L1 axis regulation in cancer therapy: the role of long non-coding RNAs and microRNAs. Life Sci. 256, 117899 (2020).
Medline CASGoogle Scholar
39. Guo L, Wei R, Lin Y et al. Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment-Current Progress, Strategy and Future Perspective. Front. Immunol. 11, 1508 (2020). •• Discusses clinical studies and patent applications related to PD-1/PD-L1 targeted therapy and progress in inhibitors of PD-1/PD-L1
Medline CASGoogle Scholar
40. University of Groningen: WO2019008152 (2019).
Google Scholar
41. University of Groningen: WO2019008154 (2019).
Google Scholar
42. University of Groningen: WO2019008156 (2019).
Google Scholar
43. Abbisko Therapeutics: WO2019149183 (2019).
Google Scholar
44. Shenzhen Chipscreen Biosciences: WO2020043154 (2020).
Google Scholar
45. Shangai Maxinovel Pharmaceuticals: WO2020088357 (2020).
Google Scholar
46. Bristol Myers Squibb: US9872852 (2018).
Google Scholar
47. Wang Y, Gu T, Tian X et al. A small molecule antagonist of PD-1/PD-L1 interactions acts as an immune checkpoint inhibitor for NSCLC and melanoma immunotherapy. Front. Immunol. 12, 654463 (2021).
Medline CASGoogle Scholar
48. Ashizawa T, Iizuka A, Tanaka E et al. Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse. Biomed. Res. 40(6), 243–250 (2019).
Medline CASGoogle Scholar
49. Zhang R, Zhu Z, Lv H et al. Immune checkpoint blockade mediated by a small-molecule nanoinhibitor targeting the PD-1/PD-L1 pathway synergizes with photodynamic therapy to elicit antitumor immunity and antimetastatic effects on breast cancer. Small 15(49), 1903881 (2019).
CASGoogle Scholar

Vol. 10, No. 6

Metrics

Downloaded 104 times

History

Received 21 July 2021

Accepted 9 November 2021

Published online 8 December 2021

Published in print November 2021

Information

Keywords

Acknowledgments

The authors would like to thank I Herrera for the critical analysis of the design of the patent evaluation. The authors thank the Mexican people for the support, through their taxes, provided for the development of this article.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download

Small-molecule inhibitor PD-1/PD-L1 interaction for colorectal cancer treatment

Abstract

References